In an interview last week, Mark Kris, an oncologist at Memorial Sloan-Kettering Hospital in New York City, said Iressa would be a useful drug.

FORBES: Magazine Article

In non-small cell lung cancer, for instance, the tissue samples needed to identify these genetic markers are not routinely taken for practical reasons, says Mark Kris , an oncologist at Memorial Sloan-Kettering Hospital in New York who has worked with Iressa and with OSI's Tarceva.

FORBES: Why Cancer Drugs Need Genetic Testing